GET DAILY SIGNALSSutro Biopharma (STRO) Q3 2026 Earnings: Pipeline Updates and Cash Runway in Focus
Key Takeaways
- Sutro Biopharma is expected to report its third-quarter 2026 results (quarter ended September 30, 2026) on November 11, 2026.
- Analyst consensus calls for a net loss of roughly $1.66 per share, compared with a loss of $0.67 per share in the same quarter last year.
- Consensus revenue stands near $13.61 million, up about 40% from the $9.69 million reported a year ago.
- Investors will focus on clinical updates for STRO-004 and other ADC (antibody drug conjugate) programs, plus the company's cash runway.
- The company missed EPS expectations in its most recent report, posting a $2.33 per-share loss versus the $2.19 consensus estimate.
- For more on STRO's Major News, Today's Price Move, Price Targets, and Forecasts, visit the dedicated pages for additional detail.
Why This Earnings Report Matters
Sutro Biopharma is a clinical-stage oncology company that develops next-generation antibody drug conjugates (ADCs) — a class of medicines designed to deliver a cancer-killing agent directly to tumor cells while sparing healthy tissue. Because the company does not yet have an approved product, its quarterly results are driven less by sales and more by collaboration revenue, clinical milestones, and research and development spending. For investors, each earnings release is a key checkpoint on pipeline progress and capital efficiency. With shares trading well below their 52-week high and the company having missed consensus in its last report, the upcoming update will be closely watched for signals on STRO-004's clinical trajectory and how far current cash can fund operations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Forecasts
Wall Street's consensus for the third quarter of 2026 calls for a net loss of approximately $1.66 per share, a notable widening from the $0.67 per-share loss reported in the third quarter of 2025. Revenue is expected to come in around $13.61 million, which would represent roughly 40% year-over-year growth from $9.69 million. As a pre-revenue biotech, Sutro's top line is largely collaboration-driven, so investors will watch the composition and timing of milestone payments rather than raw revenue alone.
The company's recent track record has been uneven. In the second quarter of 2026, Sutro reported a $2.33 per-share loss, missing the $2.19 consensus estimate, while revenue of $9.84 million fell short of the $11.96 million analysts had projected. In the first quarter of 2026, it posted a $2.94 loss per share but beat revenue expectations with $14.52 million. Beyond the headline numbers, the market will focus on updates to the STRO-004 Phase 1 study and management's guidance on operating expenses and cash runway, which are central to how long the company can sustain development without additional financing.
Recent Performance and Context
From what I see, sentiment heading into the report remains cautious. STRO stock has been volatile around recent earnings, falling roughly 15% the day after its second-quarter release in August 2026 following the EPS miss. With shares trading near the lower end of their 52-week range, the market appears to be pricing in execution risk around the pipeline and ongoing cash burn. Key risk factors ahead of the release include any delays in clinical timelines, weaker-than-expected collaboration revenue, and uncertainty around future financing needs. Conversely, a positive clinical update on STRO-004 or better-than-expected expense discipline could shift sentiment. Because the company's valuation is heavily tied to pipeline catalysts rather than near-term earnings, investors will likely react more to clinical and strategic disclosures than to the raw EPS figure itself.
What to Watch After the Release
Following the earnings release, investors should pay attention to several forward-looking themes. First is the clinical progress of STRO-004, Sutro's most advanced wholly owned ADC candidate. Any data updates, enrollment milestones, or regulatory feedback will be the most direct drivers of the investment narrative.
Second is the company's cash position and spending trajectory. As a clinical-stage biotech with no marketed products, Sutro relies on its balance sheet and collaboration revenue to fund research and development. Management's commentary on operating expense trends and cash runway will signal whether additional capital raises may be needed and on what timeline.
Third is the partnership revenue outlook. Sutro's collaboration agreements, including its ADC platform licensing relationships, generate milestone-based revenue that can be lumpy from quarter to quarter. Investors will want clarity on the timing and size of expected milestone payments.
Finally, broader industry dynamics in oncology and the ADC space remain relevant, as competition and deal activity can influence how the market values early-stage programs. Monitoring these factors together — rather than any single headline number — will offer the clearest read on the company's direction after the report. I’m watching this closely for any signs of improved capital efficiency.
Using Tickeron AI Tools for Research
In preparing for earnings season, I often turn to Tickeron’s suite of AI-driven platforms to cross-check patterns and signals across the biotech sector. One tool that stands out is the AI Screener, which lets me filter for companies with similar fundamentals and recent performance metrics. It helps surface comparable names quickly without manual effort. For those tracking earnings-driven moves in names like Sutro Biopharma, it offers a structured way to narrow the market to relevant candidates and identify potential trade ideas based on technical and fundamental criteria.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STRO sees its Stochastic Oscillator recovers from oversold territory
On November 03, 2026, the Stochastic Oscillator for STRO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 62 instances where the indicator left the oversold zone. In 53 of the 62 cases the stock moved higher in the following days. This puts the odds of a move higher at over 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STRO's RSI Oscillator exited the oversold zone, 43 of 53 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for STRO just turned positive on November 02, 2026. Looking at past instances where STRO's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
Following a +9.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where STRO advanced for three days, in 205 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
STRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STRO as a result. In 71 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for STRO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.476) is normal, around the industry mean (2.904). P/E Ratio (-0.530) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.982) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. STRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of new products in protein vaccines and therapeutics
Industry Biotechnology
Advertisement